# Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia

> **NCT05828108** · PHASE1,PHASE2 · COMPLETED · sponsor: **National Heart, Lung, and Blood Institute (NHLBI)** · enrollment: 15 (actual)

## Conditions studied

- Steroid-refractory Diamond-Blackfan Anemia (DBA)

## Interventions

- **DRUG:** Bitopertin

## Key facts

- **NCT ID:** NCT05828108
- **Lead sponsor:** National Heart, Lung, and Blood Institute (NHLBI)
- **Sponsor class:** NIH
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-07-25
- **Primary completion:** 2025-08-28
- **Final completion:** 2025-08-28
- **Target enrollment:** 15 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05828108

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05828108, "Study of the Selective GlyT1 Inhibitor Bitopertin for Steroid-Refractory Diamond-Blackfan Anemia". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05828108. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*